CancerFax
BISPECIFIC CAR-T

CD19/CD22 BISPECIFIC
CAR-T THERAPY

CD19/CD22 bispecific CAR-T targets two antigens simultaneously β€” reducing antigen escape, the main cause of CD19 CAR-T relapse. China leads global clinical experience.

Share Your ReportsRequest Guidance

analyticsAt a Glance

  • check_circleDual targeting of CD19 and CD22 reduces the risk of antigen escape relapse
  • check_circleParticularly relevant for B-cell ALL where single-target CD19 CAR-T relapse is common
  • check_circlePhase I/II data from Chinese centres shows high response rates with manageable toxicity
  • check_circleBeing evaluated for ALL, DLBCL, and other B-cell malignancies

Why Bispecific Targeting Matters

Single-antigen CD19 CAR-T fails in 30–50% of patients due to antigen escape β€” cancer cells lose CD19 and become invisible. Targeting CD19 and CD22 simultaneously makes escape much harder.

  • CD19 Antigen Escape

    CD19-negative relapse occurs in 30–50% of patients after CD19 CAR-T. The cancer mutates to stop expressing CD19 β€” making the therapy blind to it.

  • CD22 as a Complementary Target

    CD22 is expressed on most B-cell cancers independently of CD19. Targeting both requires the cancer to lose two antigens simultaneously to escape β€” a much rarer event.

CD19/CD22 Bispecific CAR-T β€” Chinese Trial Data

IndicationProduct/CentreKey Result
r/r B-ALLMultiple Chinese academicCR rates 70–90%; lower CD19-neg relapse
r/r DLBCLPUMCH, Ruijin, othersORR 60–75%; more durable remissions
Post-CD19 CAR-T relapseLu Daopei, PUMCHCR rates 40–60% in CD19-negative relapse

Frequently Asked Questions

About CD19/CD22 Bispecific CAR-T

    Related Resources

    How CancerFax Helps

    CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

    description
    Medical Record Review

    We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

    verified_user
    Eligibility Coordination

    We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

    hub
    Hospital Communication

    We support appointment coordination, document submission, translation, and direct communication with international departments.

    flight
    Travel & Admission Support

    For international patients, we help with practical coordination β€” travel planning, hospital admission guidance, and local support.

    explore
    Treatment & Trial Navigation

    If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

    support_agent
    End-to-end Coordination

    From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

    Send Medical ReportsSpeak With CancerFax

    CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

    Exploring Bispecific CAR-T?

    CancerFax reviews your B-cell cancer history to identify CD19/CD22 bispecific CAR-T trials in China.

    Share Your ReportsTalk to Our Team

    For informational purposes only. Consult a qualified haematologist before making decisions.